

API	Indication	R&D Validation batches	DMF
RESPIRATORY			
Abediterol	Asthma and COPD	early R&D	
Aclidinium bromide	COPD	R&D	
Albuterol sulfate	Asthma and COPD	√	2018
Arformoterol tartrate ^P polymorph A and D	COPD	√	√
Batefenterol	COPD	early R&D	
Formoterol fumarate	Asthma and COPD	√ ^{CoS}	√
Glycopyrronium bromide ^P	COPD	√	√
Indacaterol maleate ^P	Asthma and COPD	√	2019
Olodaterol ^P	COPD	Q2 2018	
Revefenacin	COPD	R&D	
Salbutamol sulfate	Asthma and COPD	√	2018
Salmeterol xinafoate ^P	Asthma and COPD	√ ^{CoS}	√
Tiotropium Bromide (monohydrate/anhydrate/ amorphous)	COPD	√	
Umeclidinium bromide	COPD	√	
Vilanterol trifenate	Asthma and COPD	Q2 2018	

CoS = Products with Certificate of Suitability

P = Patent applications/granted patents owned by NuPharm Group



Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.